Clinical Trials /

A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT03178552

Description:

This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.

Related Conditions:
  • Non-Small Cell Lung Carcinoma
Recruiting Status:

Recruiting

Phase:

Phase 2/Phase 3

Trial Eligibility

Document

Title

  • Brief Title: A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
  • Official Title: A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)

Clinical Trial IDs

  • ORG STUDY ID: BO29554
  • SECONDARY ID: 2017-000076-28
  • NCT ID: NCT03178552

Conditions

  • Non-Small Cell Lung Cancer

Interventions

DrugSynonymsArms
AlectinibRO5424802Cohort A: Alectinib 600 Milligrams (mg)
AtezolizumabRO5541267Cohort C: Atezolizumab 1200 mg
PemetrexedCohort C: Pemetrexed, Cisplatin or Carboplatin
CisplatinCohort C: Pemetrexed, Cisplatin or Carboplatin
CarboplatinCohort C: Pemetrexed, Cisplatin or Carboplatin
GemcitabineCohort C: Gemcitabine, Cisplatin or Carboplatin

Purpose

This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.

Trial Arms

NameTypeDescriptionInterventions
Cohort A: Alectinib 600 Milligrams (mg)ExperimentalThis cohort includes participants with anaplastic lymphoma kinase (ALK) positive NSCLC. Participants will receive alectinib 600 mg orally twice in a day (BID) until disease progression, loss of clinical benefit, unacceptable toxicity, withdrawal of consent or death.
  • Alectinib
Cohort B: Dose Finding Phase (DFP) AlectinibExperimentalThis cohort includes participants with rearranged during transfection (RET) positive NSCLC. Participants may receive alectinib 900 or 1200 mg orally BID until disease progression, loss of clinical benefit, unacceptable toxicity, withdrawal of consent or death if the recommended phase 2 dose (RP2D) is not established in any other clinical study.
  • Alectinib
Cohort B: Dose Expansion Phase (DEP) AlectinibExperimentalThis cohort includes participants with RET positive NSCLC. Participants will receive alectinib at the RP2D established in the DFP of Cohort B or a separate clinical study. Participants will continue receiving study treatment until disease progression, loss of clinical benefit, unacceptable toxicity, withdrawal of consent or death.
  • Alectinib
Cohort C: Atezolizumab 1200 mgExperimentalThis cohort includes participants with bTMB positive NSCLC. Participants will receive atezolizumab at a dose of 1200 mg administered by IV infusion every 21 days (Q21D) until disease progression, loss of clinical benefit, unacceptable toxicity, withdrawal of consent or death.
  • Atezolizumab
Cohort C: Pemetrexed, Cisplatin or CarboplatinActive ComparatorThis cohort includes participants with bTMB positive, non-squamous NSCLC. Participants will receive 4 or 6 cycles of treatment, with each cycle being 21 days in duration. Carboplatin at a dose of area under the concentration-time curve (AUC) of 5 or 6 IV or cisplatin at a dose of 75 milligrams per meter square (mg/m^2) IV on Day 1 of each cycle combined with pemetrexed at a dose of 500 mg/m^2 IV on Day 1 of each cycle. Pemetrexed may be continued as maintenance therapy every 21 days (Q21D) as per local standard of care.
  • Pemetrexed
  • Cisplatin
  • Carboplatin
Cohort C: Gemcitabine, Cisplatin or CarboplatinActive ComparatorThis cohort includes participants with bTMB positive, squamous NSCLC. Participants will receive 4 or 6 cycles of treatment, with each cycle being 21 days in duration. Gemcitabine 1250 mg/m^2 IV on Days 1 and 8 of every cycle and cisplatin 75 mg/m^2 IV on Day 1 Q21D or gemcitabine 1000 mg/m^2 IV on Days 1 and 8 of every cycle and carboplatin AUC 5 IV on Day 1 Q21D.
  • Cisplatin
  • Carboplatin
  • Gemcitabine

Eligibility Criteria

        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of unresectable Stage IIIb not
             amenable to treatment with combined modality chemoradiation (advanced) or Stage IV
             (metastatic) NSCLC

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

          -  Measurable disease

          -  Adequate recovery from most recent systemic or local treatment for cancer

          -  Adequate organ function

          -  Life expectancy greater than or equal to (>/=) 12 weeks

          -  For female participants of childbearing potential and male participants, willingness
             to use acceptable methods of contraception

        Exclusion Criteria:

          -  Inability to swallow oral medication

          -  Women who are pregnant or lactating

          -  Active or untreated CNS metastases as determined by computed tomography (CT) or
             magnetic resonance imaging (MRI) evaluation during screening and prior radiographic
             assessments

          -  History of other malignancy within 5 years prior to screening, except for
             appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma,
             in situ ductal adenocarcinoma of the breast, in situ prostate cancer, limited stage
             bladder cancer, Stage I uterine cancer, or other cancers from which the patient has
             been disease-free for at least 2 years

          -  Significant cardiovascular disease, such as New York Heart Association cardiac
             disease (Class II or greater), myocardial infarction, or cerebrovascular accident
             within 3 months prior to randomization, unstable arrhythmias, or unstable angina

          -  Known human immunodeficiency virus (HIV) positivity or autoimmune deficiency syndrome
             (AIDS)-related illness

          -  Either a concurrent condition or history of a prior condition that places the patient
             at unacceptable risk if he/she were treated with the study drug or confounds the
             ability to interpret data from the study

          -  Inability to comply with other requirements of the protocol
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Cohort A: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1
Time Frame:Baseline up to disease progression or death (up to approximately 6 years)
Safety Issue:
Description:

Secondary Outcome Measures

Measure:All Cohorts: Duration of Response as Assessed by the Investigator Based on the RECIST v1.1
Time Frame:Baseline up to disease progression or death (up to approximately 6 years)
Safety Issue:
Description:
Measure:Cohorts A and B: Percentage of Participants with Clinical Benefit Response as Assessed by the Investigator Based on the RECIST v1.1
Time Frame:Baseline up to disease progression or death (up to approximately 6 years)
Safety Issue:
Description:
Measure:Cohorts A and B: PFS as Assessed by the Investigator Based on the RECIST v1.1
Time Frame:Baseline up to disease progression or death (up to approximately 6 years)
Safety Issue:
Description:
Measure:All Cohorts: Duration of Response as Assessed by the Independent Review Facility (IRF) Based on the RECIST v1.1
Time Frame:Baseline up to disease progression or death (up to approximately 6 years)
Safety Issue:
Description:
Measure:Cohorts A and B: Percentage of Participants with Clinical Benefit Response as Assessed by IRF Based on the RECIST v1.1
Time Frame:Baseline up to disease progression or death (up to approximately 6 years)
Safety Issue:
Description:
Measure:All Cohorts: PFS as Assessed by IRF Based on the RECIST v1.1
Time Frame:Baseline up to disease progression or death (up to approximately 6 years)
Safety Issue:
Description:
Measure:All Cohorts: Percentage of Participants with Confirmed Objective Response as Assessed by IRF Based on the RECIST v1.1
Time Frame:Baseline up to disease progression or death (up to approximately 6 years)
Safety Issue:
Description:
Measure:All Cohorts: Overall Survival
Time Frame:Baseline up to approximately 6 years
Safety Issue:
Description:
Measure:All Cohorts: Percentage of Participants with Adverse Events
Time Frame:Baseline up to approximately 6 years
Safety Issue:
Description:
Measure:Cohorts A and B: Percentage of Participants who Have Shown Improvement Compared with Baseline in Total Severity Symptom Score as Measured by Symptoms in Lung Cancer (SILC) Scale in Patient-Reported Lung Cancer Symptoms (Cough, Dyspnea and Chest Pain)
Time Frame:Baseline, every 4 weeks through Cycle 6 (1 Cycle = 21 or 28 days), every 8 weeks thereafter up to approximately 6 years
Safety Issue:
Description:
Measure:All Cohorts: Time to Deterioration in Patient-Reported Lung Cancer Symptoms (Cough, Dyspnea and Chest Pain) as Measured by SILC Scale
Time Frame:Baseline, every 4 weeks through Cycle 6 (1 Cycle = 21 or 28 days), every 8 weeks thereafter up to approximately 6 years
Safety Issue:
Description:
Measure:Cohort C: Change from Baseline in Patient-Reported Lung Cancer Symptom (Cough, Dyspnea, Chest pain) Score as Measured by the SILC Scale
Time Frame:Baseline, every 4 weeks through Cycle 6 (1 Cycle = 21 or 28 days), every 8 weeks thereafter up to approximately 6 years
Safety Issue:
Description:
Measure:All Cohorts: Change from Baseline in Health Related Quality of Life (HRQoL) Scores as Measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - C30 (EORTC QLQ-C30)
Time Frame:Baseline, every 4 weeks through Cycle 6 (1 Cycle = 21 or 28 days), every 8 weeks thereafter up to approximately 6 years
Safety Issue:
Description:
Measure:Cohorts A and B: Change from Baseline in HRQoL Scores as Measured by the SILC Scale
Time Frame:Baseline, every 4 weeks through Cycle 6 (1 Cycle = 21 or 28 days), every 8 weeks thereafter up to approximately 6 years
Safety Issue:
Description:
Measure:All Cohorts: Change from Baseline in Patient Functioning and Symptoms Score as Measured by the EORTC QLQ-C30
Time Frame:Baseline, every 4 weeks through Cycle 6 (1 Cycle = 21 or 28 days), every 8 weeks thereafter up to approximately 6 years
Safety Issue:
Description:
Measure:Cohorts A and B: Change from Baseline in Patient Functioning and Symptoms Score as Measured by the SILC Scale
Time Frame:Baseline, every 4 weeks through Cycle 6 (1 Cycle = 21 or 28 days), every 8 weeks thereafter up to approximately 6 years
Safety Issue:
Description:
Measure:All Cohorts: Health Status Assessed as an Index Score Using the European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Questionnaire
Time Frame:Baseline, every 4 weeks through Cycle 6 (1 Cycle = 21 or 28 days), every 8 weeks thereafter up to approximately 6 years
Safety Issue:
Description:
Measure:Cohort B: Percentage of Participants with Dose-Limiting Toxicities (DLTs)
Time Frame:Day 1 to Day 28 of Cycle 1 (cycle length = 28 days)
Safety Issue:
Description:
Measure:Cohort B: Maximum Plasma Concentration (Cmax) of Alectinib
Time Frame:DFP: pre-dose (0 hour [hr]) on Days 1, 8 of Cycle 1 and Day 1 of Cycles 2, 3, 4; 0.5 hours (hr), 1, 2, 4, 6, 8 and 10 hr post-dose on Day 1 of Cycle 2 (1 Cycle=28 days); DEP: pre-dose (0 hr) on Day 1 of Cycles 1, 2, 3, 4 (1 Cycle=28 days)
Safety Issue:
Description:DFP: Dose-Finding Phase; DEP: Dose-Expanding Phase.
Measure:Cohort B: Area Under the Concentration-Time Curve from Time Zero to the Last Measurable Concentration (AUC0-last) of Alectinib
Time Frame:DFP: pre-dose (0 hr) on Days 1, 8 of Cycle 1 and Day 1 of Cycles 2, 3, 4; 0.5 hours (hr), 1, 2, 4, 6, 8 and 10 hr post-dose on Day 1 of Cycle 2 (1 Cycle=28 days); DEP: pre-dose (0 hr) on Day 1 of Cycles 1, 2, 3, 4 (1 Cycle=28 days)
Safety Issue:
Description:
Measure:Cohort B: Time to Reach Cmax (Tmax) of Alectinib
Time Frame:DFP: pre-dose (0 hr) on Days 1, 8 of Cycle 1 and Day 1 of Cycles 2, 3, 4; 0.5 hours (hr), 1, 2, 4, 6, 8 and 10 hr post-dose on Day 1 of Cycle 2 (1 Cycle=28 days); DEP: pre-dose (0 hr) on Day 1 of Cycles 1, 2, 3, 4 (1 Cycle=28 days)
Safety Issue:
Description:
Measure:Cohort B: Half-Life (t1/2) of Alectinib
Time Frame:DFP: pre-dose (0 hr) on Days 1, 8 of Cycle 1 and Day 1 of Cycles 2, 3, 4; 0.5 hours (hr), 1, 2, 4, 6, 8 and 10 hr post-dose on Day 1 of Cycle 2 (1 Cycle=28 days); DEP: pre-dose (0 hr) on Day 1 of Cycles 1, 2, 3, 4 (1 Cycle=28 days)
Safety Issue:
Description:
Measure:Cohort B: Metabolite to Parent Exposure Ratio for AUC0-last
Time Frame:DFP: pre-dose (0 hr) on Days 1, 8 of Cycle 1 and Day 1 of Cycles 2, 3, 4; 0.5 hours (hr), 1, 2, 4, 6, 8 and 10 hr post-dose on Day 1 of Cycle 2 (1 Cycle=28 days); DEP: pre-dose (0 hr) on Day 1 of Cycles 1, 2, 3, 4 (1 Cycle=28 days)
Safety Issue:
Description:
Measure:Cohort B: Metabolite to Parent Exposure Ratio for Cmax
Time Frame:DFP: pre-dose (0 hr) on Days 1, 8 of Cycle 1 and Day 1 of Cycles 2, 3, 4; 0.5 hours (hr), 1, 2, 4, 6, 8 and 10 hr post-dose on Day 1 of Cycle 2 (1 Cycle=28 days); DEP: pre-dose (0 hr) on Day 1 of Cycles 1, 2, 3, 4 (1 Cycle=28 days)
Safety Issue:
Description:
Measure:Cohort C: Percentage of Participants with Objective Response as Assessed by the Investigator Based on the RECIST v1.1
Time Frame:Baseline up to disease progression or death (up to approximately 6 years)
Safety Issue:
Description:
Measure:Cohort C: Percentage of Participants Free from Disease Progression as Assessed by the Investigator Based on the RECIST v1.1 at Months 6 and 12
Time Frame:Months 6, 12
Safety Issue:
Description:

Details

Phase:Phase 2/Phase 3
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:Hoffmann-La Roche

Last Updated

June 5, 2017